Brief: MEI Pharma Initiates Strategic Realignment
05/12/2022 22:32
Dec 5 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA INITIATES STRATEGIC REALIGNMENT
* MEI EXPECTS EXISTING CASH SUFFICIENT TO FUND THROUGH
CLINICAL
DATA MILESTONES FOR VORUCICLIB AND ME-344
* COMPANY CONTINUING DEVELOPMENT EFFORTS ON ITS TWO EARLY
CLINICAL-STAGE ONCOLOGY ASSETS: VORUCICLIB AND ME-344
* CO HAS ENGAGED TORREYA PARTNERS AS FINANCIAL ADVISOR TO
HELP
EXPLORE ADDITIONAL STRATEGIC OPPORTUNITIES
* PLANS TO STREAMLINE ITS ORGANIZATION TOWARDS DEVELOPMENT
OF TWO
EARLIER CLINICAL-STAGE ASSETS, VORUCICLIB AND ME-344
* TO INITIATE A STAGGERED WORKFORCE REDUCTION, REPRESENTING
ABOUT
30% OF CURRENT WORKFORCE
* STAGGERED WORKFORCE REDUCTION IN CONNECTION WITH WIND DOWN
OF
ZANDELISIB DEVELOPMENT PROGRAM OUTSIDE OF JAPAN
Source text for Eikon: ID:nBw8xZWZFa
Further company coverage: MEIP.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations